About Taho Pharma
Taho Pharma is a publicly listed company based in Taipei (Taiwan) founded in 2010. Company developing CNS and oncology drugs through their proprietary transepithelial drug delivery systems. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Taho Pharma is a speciality pharma company developing novel CNS and oncology drugs through their proprietary drug delivery platform. The companys transdermal delivery system allows the active ingredient is absorbed by the skin and distributed through the bloodstream and have capabilities for long-term controlled release and consistent plasma concentration. Their transmucosal drug delivery system which delivers drugs through orally dissolving films (ODFs), can facilitate faster onset and may avoid the first-pass effect, and can be formulated for both immediate (oralsublingual) and controlled release (buccalgum) delivery forms. The company has developed transdermal patches for Alzheimers, Schizophrenia, and epilepsy and an oral solution for ADHD and anti-emetic OD films for oncology support.
- Headquarters Taipei, Taiwan
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website tahopharma.com
- Legal Name Taho Pharmaceuticals Ltd
- Annual Revenue$8.41 Mas on Dec 31, 2025
- Net Profit-$214.4 M-28.05as on Dec 31, 2025
- EBITDA-$211.48 M-29.64as on Dec 31, 2025
IPO & Listings of Taho Pharma
Taho Pharma is a publicly listed company on the TPEX with ticker symbol 6467 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Dec 2024
- Listed onTT: 6467
- Listed entityTAHO Pharmaceuticals Ltd
- Exchange sectorHealth technology
- ISINTW0006467004
- Share price227.50 TWD (-0.22% on the day) · 2026-10-14
- Market capitalisation11,949,164,246.00 TWD
- Volume (last session)416,755
Financials of Taho Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 8.4M TWD | -214.4M TWD | -211.5M TWD |
| 2024 | -167.4M TWD | -163.1M TWD | |
| 2023 | 1.1M TWD | -120.7M TWD | -113.3M TWD |
| 2022 | 6.4M TWD | -66.3M TWD | -57.8M TWD |
| 2021 | 6.9M TWD | -11.4M TWD | -65.2M TWD |
Detailed financial statements for Taho Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Taho Pharma
The website of Taho Pharma (tahopharma.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 17.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Taho Pharma
Complete news archive for Taho Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Taho Pharma
Taho Pharma was founded in 2010.
Taho Pharma is headquartered in Taipei, Taiwan.
Taho Pharma is a speciality pharma company developing novel CNS and oncology drugs through their proprietary drug delivery platform. The companys transdermal delivery system allows the active ingredient is absorbed by the skin and distributed through the bloodstream and have capabilities for long-term controlled release and consistent plasma concentration. Their transmucosal drug delivery system which delivers drugs through orally dissolving films (ODFs), can facilitate faster onset and may avoid the first-pass effect, and can be formulated for both immediate (oralsublingual) and controlled release (buccalgum) delivery forms. The company has developed transdermal patches for Alzheimers, Schizophrenia, and epilepsy and an oral solution for ADHD and anti-emetic OD films for oncology support.
Yes, Taho Pharma is publicly traded on TPEX under the ticker symbol 6467.